[
  {
    "ts": null,
    "headline": "Health Care Roundup: Market Talk",
    "summary": "Gain insight on Pfizer’s purchase of Metsera, Roche’s fenebrutinib results, and more in the latest Market Talks covering the health care sector.",
    "url": "https://finnhub.io/api/news?id=5b4f1bad4c152375324ea15381d2708dd9af0f1c270a73850669fe080364e10a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762811940,
      "headline": "Health Care Roundup: Market Talk",
      "id": 137437841,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Gain insight on Pfizer’s purchase of Metsera, Roche’s fenebrutinib results, and more in the latest Market Talks covering the health care sector.",
      "url": "https://finnhub.io/api/news?id=5b4f1bad4c152375324ea15381d2708dd9af0f1c270a73850669fe080364e10a"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. (PFE) Discusses Clinical Development Strategy for 4404 Bispecific Antibody in Oncology - Slideshow",
    "summary": "2025-11-10. The following slide deck was published by Pfizer Inc.",
    "url": "https://finnhub.io/api/news?id=c8183e25261008362dc62acf74af60130e642cfa55f3c2d27b72426e8e8d4431",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762810374,
      "headline": "Pfizer Inc. (PFE) Discusses Clinical Development Strategy for 4404 Bispecific Antibody in Oncology - Slideshow",
      "id": 137422946,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "2025-11-10. The following slide deck was published by Pfizer Inc.",
      "url": "https://finnhub.io/api/news?id=c8183e25261008362dc62acf74af60130e642cfa55f3c2d27b72426e8e8d4431"
    }
  },
  {
    "ts": null,
    "headline": "These Stocks Moved the Most Today: Metsera, Nvidia, Tesla, Rumble, MP Materials, Viasat, Monday.com, CoreWeave, and More",
    "summary": "Metsera falls sharply after Pfizer agrees to buy the weight-loss drug start-up in a deal that could be worth more than $10 billion.",
    "url": "https://finnhub.io/api/news?id=a4e0e4a2c6a5fc240f484488ca1a9f7cd116334c2a48c8fb92de4cfc2fd495fe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762809300,
      "headline": "These Stocks Moved the Most Today: Metsera, Nvidia, Tesla, Rumble, MP Materials, Viasat, Monday.com, CoreWeave, and More",
      "id": 137437642,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Metsera falls sharply after Pfizer agrees to buy the weight-loss drug start-up in a deal that could be worth more than $10 billion.",
      "url": "https://finnhub.io/api/news?id=a4e0e4a2c6a5fc240f484488ca1a9f7cd116334c2a48c8fb92de4cfc2fd495fe"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Advance Late Afternoon",
    "summary": "Health care stocks rose late Monday afternoon with the NYSE Health Care Index adding 0.8% and the He",
    "url": "https://finnhub.io/api/news?id=cd84ce8ffc7b66ad7fe0c88ac84d6e31fa319678011d9a0abb204b453f0b66a8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762808481,
      "headline": "Sector Update: Health Care Stocks Advance Late Afternoon",
      "id": 137437658,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Health care stocks rose late Monday afternoon with the NYSE Health Care Index adding 0.8% and the He",
      "url": "https://finnhub.io/api/news?id=cd84ce8ffc7b66ad7fe0c88ac84d6e31fa319678011d9a0abb204b453f0b66a8"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Advance Monday Afternoon",
    "summary": "Health care stocks rose Monday afternoon with the NYSE Health Care Index and the Health Care Select",
    "url": "https://finnhub.io/api/news?id=2ab053dc51fd0454605463a90468d9e0a37ec83ae864738a907ed0f4fc5316d2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762800548,
      "headline": "Sector Update: Health Care Stocks Advance Monday Afternoon",
      "id": 137437845,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Health care stocks rose Monday afternoon with the NYSE Health Care Index and the Health Care Select",
      "url": "https://finnhub.io/api/news?id=2ab053dc51fd0454605463a90468d9e0a37ec83ae864738a907ed0f4fc5316d2"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Wins Obesity Drug Battle, With Assist By Trump’s FTC",
    "summary": "Late Friday, after a dramatic bidding war, he learned he’d finally claimed his prize.  Bourla found out at around 9 p.m. that evening, according to people familiar with the matter, that the board of Metsera Inc., a three-year-old biotech startup developing a new generation of weight-loss drugs, had voted unanimously to accept Pfizer’s takeover offer of as much as $10 billion.  It was the climax of a Wall Street duel that had pitted Pfizer against the Danish pharmaceutical giant Novo Nordisk A/S – and a deal that is poised to set the global drug industry’s pecking order for years to come.",
    "url": "https://finnhub.io/api/news?id=d76e47353eb17eb90ea7559d1a4686481246f3424c4d731720917af2f86d4854",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762798187,
      "headline": "Pfizer Wins Obesity Drug Battle, With Assist By Trump’s FTC",
      "id": 137396672,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Late Friday, after a dramatic bidding war, he learned he’d finally claimed his prize.  Bourla found out at around 9 p.m. that evening, according to people familiar with the matter, that the board of Metsera Inc., a three-year-old biotech startup developing a new generation of weight-loss drugs, had voted unanimously to accept Pfizer’s takeover offer of as much as $10 billion.  It was the climax of a Wall Street duel that had pitted Pfizer against the Danish pharmaceutical giant Novo Nordisk A/S – and a deal that is poised to set the global drug industry’s pecking order for years to come.",
      "url": "https://finnhub.io/api/news?id=d76e47353eb17eb90ea7559d1a4686481246f3424c4d731720917af2f86d4854"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Clinches $10 Billion Deal for Metsera After Fierce Bidding War With Novo Nordisk",
    "summary": "The win gives Pfizer a long-awaited foothold in the fast-growing obesity drug market.",
    "url": "https://finnhub.io/api/news?id=0abd4ee893e20bec1a687175de666428b14e933b96cf252e84b768528250e261",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762797470,
      "headline": "Pfizer Clinches $10 Billion Deal for Metsera After Fierce Bidding War With Novo Nordisk",
      "id": 137396673,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The win gives Pfizer a long-awaited foothold in the fast-growing obesity drug market.",
      "url": "https://finnhub.io/api/news?id=0abd4ee893e20bec1a687175de666428b14e933b96cf252e84b768528250e261"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk: Buy This Bargain",
    "summary": "Novo Nordisk A/S posted solid revenue and profit increases, with a resilient pipeline and strong dividend yield. Learn more about NVO stock here.",
    "url": "https://finnhub.io/api/news?id=16109542cf9c778e04e5ee203b161d83f5813b097ad076908cee2f02c56f1feb",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762795733,
      "headline": "Novo Nordisk: Buy This Bargain",
      "id": 137410151,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2153927815/image_2153927815.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk A/S posted solid revenue and profit increases, with a resilient pipeline and strong dividend yield. Learn more about NVO stock here.",
      "url": "https://finnhub.io/api/news?id=16109542cf9c778e04e5ee203b161d83f5813b097ad076908cee2f02c56f1feb"
    }
  },
  {
    "ts": null,
    "headline": "Top Midday Stories: Over 1,400 Flights Canceled Monday and Counting; Pfizer to Acquire Metsera for up to $86.25 per Share",
    "summary": "The Nasdaq Composite and S&P 500 were up in late-morning trading Monday, while the Dow Jones Industr",
    "url": "https://finnhub.io/api/news?id=1056f3cfae266201abd79cc3767c829c1adb5d61222b57f7f55b0b8d154a868f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762793072,
      "headline": "Top Midday Stories: Over 1,400 Flights Canceled Monday and Counting; Pfizer to Acquire Metsera for up to $86.25 per Share",
      "id": 137396675,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The Nasdaq Composite and S&P 500 were up in late-morning trading Monday, while the Dow Jones Industr",
      "url": "https://finnhub.io/api/news?id=1056f3cfae266201abd79cc3767c829c1adb5d61222b57f7f55b0b8d154a868f"
    }
  },
  {
    "ts": null,
    "headline": "NVO: Novo Nordisk Climbs After Dropping Out of Bidding War for Metsera",
    "summary": "Novo Nordisk Shares Pop After Stepping Back From Metsera Chase",
    "url": "https://finnhub.io/api/news?id=d714b19d922c0aae742a5244e33371a1a44a35c3ad95d5c19325195de3698d34",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762792194,
      "headline": "NVO: Novo Nordisk Climbs After Dropping Out of Bidding War for Metsera",
      "id": 137396676,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Novo Nordisk Shares Pop After Stepping Back From Metsera Chase",
      "url": "https://finnhub.io/api/news?id=d714b19d922c0aae742a5244e33371a1a44a35c3ad95d5c19325195de3698d34"
    }
  },
  {
    "ts": null,
    "headline": "Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates?",
    "summary": "Alto Neuroscience, Autolus Therapeutics, Ascendis Pharma and Immuneering are gearing up to report Q3 results that could top expectations.",
    "url": "https://finnhub.io/api/news?id=877f405f48fd14d51729b48bb9c43bc2eb55d994dcd1734202be682688a5bfe5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762791660,
      "headline": "Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates?",
      "id": 137396561,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Alto Neuroscience, Autolus Therapeutics, Ascendis Pharma and Immuneering are gearing up to report Q3 results that could top expectations.",
      "url": "https://finnhub.io/api/news?id=877f405f48fd14d51729b48bb9c43bc2eb55d994dcd1734202be682688a5bfe5"
    }
  },
  {
    "ts": null,
    "headline": "Metsera (MTSR) Shares Nosedive After Pfizer Clinches Weight-Loss Biotech Deal",
    "summary": "Metsera Plunges After Pfizer Secures Revised $86-Per-Share Merger Deal",
    "url": "https://finnhub.io/api/news?id=bdbb739c38992073f7595a76a87cbaf7a0cb74e83095ad68ddd0a6acb4f322bf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762789765,
      "headline": "Metsera (MTSR) Shares Nosedive After Pfizer Clinches Weight-Loss Biotech Deal",
      "id": 137396679,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Metsera Plunges After Pfizer Secures Revised $86-Per-Share Merger Deal",
      "url": "https://finnhub.io/api/news?id=bdbb739c38992073f7595a76a87cbaf7a0cb74e83095ad68ddd0a6acb4f322bf"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Walks Away from $10 Billion Fight--And the Stock Rallies Anyway",
    "summary": "Pfizer wins Metsera after antitrust warning derails Novo's $9B bid; investors reward financial discipline over deal chasing.",
    "url": "https://finnhub.io/api/news?id=68036e72520ca4b7516b26b9a6e6348fdbf24640d9f9922ce34776a8b994f46b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762789501,
      "headline": "Novo Nordisk Walks Away from $10 Billion Fight--And the Stock Rallies Anyway",
      "id": 137396680,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer wins Metsera after antitrust warning derails Novo's $9B bid; investors reward financial discipline over deal chasing.",
      "url": "https://finnhub.io/api/news?id=68036e72520ca4b7516b26b9a6e6348fdbf24640d9f9922ce34776a8b994f46b"
    }
  },
  {
    "ts": null,
    "headline": "What’s Next for Novo Nordisk?",
    "summary": "After losing out to Pfizer for a weight-loss drug startup, Novo Nordisk will now have to count more heavily on its own research labs for new drugs, even as it’s likely to continue to pursue other deals.  Novo Nordisk’s near-term focus is to launch a pill form of Wegovy, the popular weight-loss drug it first launched in 2021 as a weekly injectable.  Novo Nordisk has applied for Food and Drug Administration approval, and expects a decision by year end.",
    "url": "https://finnhub.io/api/news?id=88be7d0fe0dac9fb2bce34aab3f251b0cb63d3597e5272561b3752fb33d89530",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762788966,
      "headline": "What’s Next for Novo Nordisk?",
      "id": 137396563,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "After losing out to Pfizer for a weight-loss drug startup, Novo Nordisk will now have to count more heavily on its own research labs for new drugs, even as it’s likely to continue to pursue other deals.  Novo Nordisk’s near-term focus is to launch a pill form of Wegovy, the popular weight-loss drug it first launched in 2021 as a weekly injectable.  Novo Nordisk has applied for Food and Drug Administration approval, and expects a decision by year end.",
      "url": "https://finnhub.io/api/news?id=88be7d0fe0dac9fb2bce34aab3f251b0cb63d3597e5272561b3752fb33d89530"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer shows hardball mettle needed to win in 2025 M&A",
    "summary": "On September 22, Pfizer announced a deal to acquire the shares of promising weight-loss drug start-up Metsera for $5.5bn. On Friday night Metsera...",
    "url": "https://finnhub.io/api/news?id=dfe1acacbd0537b737f48165abd2c034cd0f250385b3b3c4b88f2c8e271a2e89",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762788887,
      "headline": "Pfizer shows hardball mettle needed to win in 2025 M&A",
      "id": 137437846,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "On September 22, Pfizer announced a deal to acquire the shares of promising weight-loss drug start-up Metsera for $5.5bn. On Friday night Metsera...",
      "url": "https://finnhub.io/api/news?id=dfe1acacbd0537b737f48165abd2c034cd0f250385b3b3c4b88f2c8e271a2e89"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk shares rise on investor relief after it exits Metsera bid",
    "summary": "STORY: Shares in Novo Nordisk rose on Monday (November 10).Investors bought in after the Wegovy maker lost out to Pfizer in a $10 billion bidding war for U.S. biotech Metsera.Market watchers saw its offer as too complex.The Danish drugmaker has also come under more pressure over governance.That after Norway's sovereign wealth fund said it would abstain when Novo shareholders vote this week on a new board.Pfizer said late Friday it had secured a deal for obesity drug developer Metsera.It was a setback for Novo as it tries to compete with rival Eli Lilly in the weight-loss drug market.Novo had started the bidding war in late October with an unsolicited offer a month after Metsera and Pfizer agreed a deal.The U.S. Federal Trade Commission told Novo and Metsera last week their proposed deal risked breaking U.S. antitrust laws.Metsera cited the antitrust concerns in rejecting Novo's bid.The Danish drugmaker confirmed Saturday it would withdraw from the race.Novo's shares were up 2.6% by Monday afternoon.The stock has lost more than 70% of its value since June last year.",
    "url": "https://finnhub.io/api/news?id=6b54538828a6fe802a9e40f19ea645845b43b570d8b839ee49ae756a45d90606",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762786630,
      "headline": "Novo Nordisk shares rise on investor relief after it exits Metsera bid",
      "id": 137394828,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "STORY: Shares in Novo Nordisk rose on Monday (November 10).Investors bought in after the Wegovy maker lost out to Pfizer in a $10 billion bidding war for U.S. biotech Metsera.Market watchers saw its offer as too complex.The Danish drugmaker has also come under more pressure over governance.That after Norway's sovereign wealth fund said it would abstain when Novo shareholders vote this week on a new board.Pfizer said late Friday it had secured a deal for obesity drug developer Metsera.It was a setback for Novo as it tries to compete with rival Eli Lilly in the weight-loss drug market.Novo had started the bidding war in late October with an unsolicited offer a month after Metsera and Pfizer agreed a deal.The U.S. Federal Trade Commission told Novo and Metsera last week their proposed deal risked breaking U.S. antitrust laws.Metsera cited the antitrust concerns in rejecting Novo's bid.The Danish drugmaker confirmed Saturday it would withdraw from the race.Novo's shares were up 2.6% by Monday afternoon.The stock has lost more than 70% of its value since June last year.",
      "url": "https://finnhub.io/api/news?id=6b54538828a6fe802a9e40f19ea645845b43b570d8b839ee49ae756a45d90606"
    }
  },
  {
    "ts": null,
    "headline": "Metsera Tumbles After The Pfizer-Novo Buyout Battle Ends At $10 Billion",
    "summary": "Metsera stock toppled Monday after the buyout battle with Pfizer and Novo Nordisk ended. Pfizer will acquire Metsera for up to $10 billion.",
    "url": "https://finnhub.io/api/news?id=6bb4611026962ab2cdb5e0f33c19777fa7b317a6b026b73922f87f4e64db25cc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762786321,
      "headline": "Metsera Tumbles After The Pfizer-Novo Buyout Battle Ends At $10 Billion",
      "id": 137395034,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Metsera stock toppled Monday after the buyout battle with Pfizer and Novo Nordisk ended. Pfizer will acquire Metsera for up to $10 billion.",
      "url": "https://finnhub.io/api/news?id=6bb4611026962ab2cdb5e0f33c19777fa7b317a6b026b73922f87f4e64db25cc"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to Watch Monday: Barrick Mining, TSMC, Metsera, Tyson Foods",
    "summary": "↗️ TSMC (TSM, TW:2330): The contract chip maker's sales rose last month at the slowest pace since February 2024, but remained in double-digits. U.S.-listed American depositary receipts rose about 3%, part of a broader rebound in technology stocks.",
    "url": "https://finnhub.io/api/news?id=8f55038ebe66e43c2ffe119cf7768defe5583f216c1b2b163017411359e1fe26",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762785813,
      "headline": "Stocks to Watch Monday: Barrick Mining, TSMC, Metsera, Tyson Foods",
      "id": 137395035,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "↗️ TSMC (TSM, TW:2330): The contract chip maker's sales rose last month at the slowest pace since February 2024, but remained in double-digits. U.S.-listed American depositary receipts rose about 3%, part of a broader rebound in technology stocks.",
      "url": "https://finnhub.io/api/news?id=8f55038ebe66e43c2ffe119cf7768defe5583f216c1b2b163017411359e1fe26"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Wins Obesity War Against NVO, to Buy Metsera for Around $10B",
    "summary": "Pfizer secures a $10B deal to buy Metsera, ending its fierce bidding war with Novo Nordisk and reigniting its push into the obesity market.",
    "url": "https://finnhub.io/api/news?id=d70cd3a0f11afe1b474546275dee7a03f52f024449feb27424b6eadee4ad1b15",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762785720,
      "headline": "Pfizer Wins Obesity War Against NVO, to Buy Metsera for Around $10B",
      "id": 137396683,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer secures a $10B deal to buy Metsera, ending its fierce bidding war with Novo Nordisk and reigniting its push into the obesity market.",
      "url": "https://finnhub.io/api/news?id=d70cd3a0f11afe1b474546275dee7a03f52f024449feb27424b6eadee4ad1b15"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer & Metsera, Monday.com, Instacart: Trending Tickers",
    "summary": "Morning Brief host Julie Hyman tracks several of the day's top trending stock tickers, including Pfizer (PFE) outbidding Novo Nordisk (NVO) in its acquisition of Metsera (MTSR), monday.com (MNDY) shares diving nearly 20% in Monday's premarket after falling short of revenue forecast estimates, and Instacart (CART) — which operates as Maplebear, Inc. — beating its third quarter earnings estimates. To watch more expert insights and analysis on the latest market action, check out more Morning Brief.",
    "url": "https://finnhub.io/api/news?id=62396f18ddbae63dbbc13ab504253420dfc350d01765af8e44c250e62b3cac33",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762785186,
      "headline": "Pfizer & Metsera, Monday.com, Instacart: Trending Tickers",
      "id": 137395036,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Morning Brief host Julie Hyman tracks several of the day's top trending stock tickers, including Pfizer (PFE) outbidding Novo Nordisk (NVO) in its acquisition of Metsera (MTSR), monday.com (MNDY) shares diving nearly 20% in Monday's premarket after falling short of revenue forecast estimates, and Instacart (CART) — which operates as Maplebear, Inc. — beating its third quarter earnings estimates. To watch more expert insights and analysis on the latest market action, check out more Morning Brief.",
      "url": "https://finnhub.io/api/news?id=62396f18ddbae63dbbc13ab504253420dfc350d01765af8e44c250e62b3cac33"
    }
  },
  {
    "ts": null,
    "headline": "Cogent: Another Win For Bezuclastinib In GIST Warrants Continued Strong Buy",
    "summary": "Cogent Biosciences, Inc. earns a Strong Buy rating due to positive phase 3 PEAK results for bezuclastinib + Sunitinib. Read more on COGT stock here.",
    "url": "https://finnhub.io/api/news?id=a6f808fa022f7f668bd66a6e913d4b41c4dabe9b5c38553593c4fef0349fbf11",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762784868,
      "headline": "Cogent: Another Win For Bezuclastinib In GIST Warrants Continued Strong Buy",
      "id": 137399545,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2242604824/image_2242604824.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Cogent Biosciences, Inc. earns a Strong Buy rating due to positive phase 3 PEAK results for bezuclastinib + Sunitinib. Read more on COGT stock here.",
      "url": "https://finnhub.io/api/news?id=a6f808fa022f7f668bd66a6e913d4b41c4dabe9b5c38553593c4fef0349fbf11"
    }
  },
  {
    "ts": null,
    "headline": "Investors Monitor Potential Breakthrough to End Government Shutdown, Driving Premarket Gains for US Equity Futures",
    "summary": "US equity futures were up ahead of Monday's opening bell as traders monitored a potential breakthrou",
    "url": "https://finnhub.io/api/news?id=fc2e50c45b75e0a0cb7debbc87f09b79e59df986c94994bfa1805b1537c08ad7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762784090,
      "headline": "Investors Monitor Potential Breakthrough to End Government Shutdown, Driving Premarket Gains for US Equity Futures",
      "id": 137395037,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "US equity futures were up ahead of Monday's opening bell as traders monitored a potential breakthrou",
      "url": "https://finnhub.io/api/news?id=fc2e50c45b75e0a0cb7debbc87f09b79e59df986c94994bfa1805b1537c08ad7"
    }
  },
  {
    "ts": null,
    "headline": "Here Are Monday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Alphabet, Apple, Eli Lilly, CarMax, HubSpot, and More",
    "summary": "Pre-Market Stock Futures: The futures are trading higher as the new week begins, with most investors and traders relieved that last week has come to a close. Hopes that an end to the Government shutdown in Congress is driving the futures higher this morning. The same mantra that was chanted last week — AI/Bubble, stocks ... Here Are Monday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Alphabet, Apple, Eli Lilly, CarMax, HubSpot, and More",
    "url": "https://finnhub.io/api/news?id=f7ec01129817f3397dc80aca48da63aee5b5135dd7d6e52a2d9f3c77ef6f54bd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762783862,
      "headline": "Here Are Monday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Alphabet, Apple, Eli Lilly, CarMax, HubSpot, and More",
      "id": 137394702,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pre-Market Stock Futures: The futures are trading higher as the new week begins, with most investors and traders relieved that last week has come to a close. Hopes that an end to the Government shutdown in Congress is driving the futures higher this morning. The same mantra that was chanted last week — AI/Bubble, stocks ... Here Are Monday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Alphabet, Apple, Eli Lilly, CarMax, HubSpot, and More",
      "url": "https://finnhub.io/api/news?id=f7ec01129817f3397dc80aca48da63aee5b5135dd7d6e52a2d9f3c77ef6f54bd"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=c89ceccc976f2e38ef8f6afc514ce7d2cb882742d8d817dce5bc899352a3bce7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762783203,
      "headline": "Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know",
      "id": 137395039,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=c89ceccc976f2e38ef8f6afc514ce7d2cb882742d8d817dce5bc899352a3bce7"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Gains 7.2% in a Month:  Buy, Sell or Hold the Stock?",
    "summary": "Bristol Myers Squibb's strong Q3 driven by soaring demand for Opdivo, Reblozyl, Breyanzi and Camzyos pushes shares up 7.2% in a month.",
    "url": "https://finnhub.io/api/news?id=cc7a183f7fe3cd4d840142981899394dab95a0a36ec28cb1312070c9882682ea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762782840,
      "headline": "Bristol Myers Gains 7.2% in a Month:  Buy, Sell or Hold the Stock?",
      "id": 137394959,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Bristol Myers Squibb's strong Q3 driven by soaring demand for Opdivo, Reblozyl, Breyanzi and Camzyos pushes shares up 7.2% in a month.",
      "url": "https://finnhub.io/api/news?id=cc7a183f7fe3cd4d840142981899394dab95a0a36ec28cb1312070c9882682ea"
    }
  },
  {
    "ts": null,
    "headline": "Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday Amid Hopes of Government Reopening",
    "summary": "The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up nearly 1% and the actively",
    "url": "https://finnhub.io/api/news?id=af95f7758682318ff60ed3d44c817db933b080600cf345b3dcc7c3ef57e3619a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762782634,
      "headline": "Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday Amid Hopes of Government Reopening",
      "id": 137394615,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up nearly 1% and the actively",
      "url": "https://finnhub.io/api/news?id=af95f7758682318ff60ed3d44c817db933b080600cf345b3dcc7c3ef57e3619a"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Wins Battle for Weight-Loss Drugmaker Metsera. Why Novo Nordisk Is the Real Winner.",
    "summary": "The Danish drugmaker's shareholders appear relieved that it hasn't overpaid for largely unproven treatments.",
    "url": "https://finnhub.io/api/news?id=ec891d76b2a72af29fc2d41a1273d24ad8751bfc8c5e8c97ca0d945e9dad1018",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762781580,
      "headline": "Pfizer Wins Battle for Weight-Loss Drugmaker Metsera. Why Novo Nordisk Is the Real Winner.",
      "id": 137395042,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The Danish drugmaker's shareholders appear relieved that it hasn't overpaid for largely unproven treatments.",
      "url": "https://finnhub.io/api/news?id=ec891d76b2a72af29fc2d41a1273d24ad8751bfc8c5e8c97ca0d945e9dad1018"
    }
  },
  {
    "ts": null,
    "headline": "5 Things to Know Before the Stock Market Opens",
    "summary": "News of the day for Nov. 10, 2025",
    "url": "https://finnhub.io/api/news?id=355bf36274a82d6f89ee9156907892f5171298330ba56dca6a4c525531367ce9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762780277,
      "headline": "5 Things to Know Before the Stock Market Opens",
      "id": 137395043,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "News of the day for Nov. 10, 2025",
      "url": "https://finnhub.io/api/news?id=355bf36274a82d6f89ee9156907892f5171298330ba56dca6a4c525531367ce9"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer clinches $10bn Metsera deal as Novo Nordisk retreats",
    "summary": "Pfizer’s US antitrust law play appears to have won the day, with Metsera choosing the less risky offer.",
    "url": "https://finnhub.io/api/news?id=f261cb488d5b90e84f1fb14da01c0d09f28641e41cae33c197fcf47a17ffa9d8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762780103,
      "headline": "Pfizer clinches $10bn Metsera deal as Novo Nordisk retreats",
      "id": 137395044,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer’s US antitrust law play appears to have won the day, with Metsera choosing the less risky offer.",
      "url": "https://finnhub.io/api/news?id=f261cb488d5b90e84f1fb14da01c0d09f28641e41cae33c197fcf47a17ffa9d8"
    }
  },
  {
    "ts": null,
    "headline": "Does Trump's MFN Policy Put Pharma ETFs in the Crosshairs?",
    "summary": "With Trump's MFN policy cutting U.S. drug prices, will Pharma ETFs such as IHE, heavily weighted toward Eli Lilly and Novo Nordisk, lose momentum?",
    "url": "https://finnhub.io/api/news?id=16a7a39cbe1e3d6a77b7a44f7c1022483a87f9ccad15040db0e2e6567d3ce4e8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762778820,
      "headline": "Does Trump's MFN Policy Put Pharma ETFs in the Crosshairs?",
      "id": 137394837,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "With Trump's MFN policy cutting U.S. drug prices, will Pharma ETFs such as IHE, heavily weighted toward Eli Lilly and Novo Nordisk, lose momentum?",
      "url": "https://finnhub.io/api/news?id=16a7a39cbe1e3d6a77b7a44f7c1022483a87f9ccad15040db0e2e6567d3ce4e8"
    }
  },
  {
    "ts": null,
    "headline": "These Stocks Are Moving the Most Today: Metsera, Pfizer, Nvidia, Tesla, Rumble, Monday.com, CoreWeave, and More",
    "summary": "Metsera falls sharply after Pfizer agrees to buy the weight-loss drug start-up in a deal that could be worth more than $10 billion.",
    "url": "https://finnhub.io/api/news?id=1fa5a62eb2192768138aeea013f947d87b98c0d59e34606ebaac470e1c31af54",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762777980,
      "headline": "These Stocks Are Moving the Most Today: Metsera, Pfizer, Nvidia, Tesla, Rumble, Monday.com, CoreWeave, and More",
      "id": 137394816,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Metsera falls sharply after Pfizer agrees to buy the weight-loss drug start-up in a deal that could be worth more than $10 billion.",
      "url": "https://finnhub.io/api/news?id=1fa5a62eb2192768138aeea013f947d87b98c0d59e34606ebaac470e1c31af54"
    }
  },
  {
    "ts": null,
    "headline": "Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors",
    "summary": "Dr. Dansey, formerly of Pfizer and Seagen, strengthens the Board’s research, drug development and commercialization expertiseSAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune diseases, today announced the appointment of Roger Dansey, M.D., to its board of directors. Dr. Dansey, who previ",
    "url": "https://finnhub.io/api/news?id=a61f87d86c5d1f865d06ba58b9a3f7155dd14bd526cb7a9aeb0c196ef4334022",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762776000,
      "headline": "Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors",
      "id": 137395048,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Dr. Dansey, formerly of Pfizer and Seagen, strengthens the Board’s research, drug development and commercialization expertiseSAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune diseases, today announced the appointment of Roger Dansey, M.D., to its board of directors. Dr. Dansey, who previ",
      "url": "https://finnhub.io/api/news?id=a61f87d86c5d1f865d06ba58b9a3f7155dd14bd526cb7a9aeb0c196ef4334022"
    }
  },
  {
    "ts": null,
    "headline": "Olema Oncology Reports Third Quarter 2025 Financial and Operating Results",
    "summary": "Announced new clinical trial agreement with Pfizer to evaluate palazestrant in combination with atirmociclib in ER+/HER2- metastatic breast cancerInitiated OPERA-02 Phase 3 trial of palazestrant in combination with ribociclib in frontline ER+/HER2- metastatic breast cancerPresented compelling new data from Phase 1b/2 study of palazestrant plus ribociclib at ESMO 2025Ended the quarter with $329.0 million in cash, cash equivalents, and marketable securities SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWS",
    "url": "https://finnhub.io/api/news?id=a18b058a0fb13ae4b9d62938f3a60576e22b1481b9efc921c2b4fe647de62b81",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762776000,
      "headline": "Olema Oncology Reports Third Quarter 2025 Financial and Operating Results",
      "id": 137395047,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Announced new clinical trial agreement with Pfizer to evaluate palazestrant in combination with atirmociclib in ER+/HER2- metastatic breast cancerInitiated OPERA-02 Phase 3 trial of palazestrant in combination with ribociclib in frontline ER+/HER2- metastatic breast cancerPresented compelling new data from Phase 1b/2 study of palazestrant plus ribociclib at ESMO 2025Ended the quarter with $329.0 million in cash, cash equivalents, and marketable securities SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWS",
      "url": "https://finnhub.io/api/news?id=a18b058a0fb13ae4b9d62938f3a60576e22b1481b9efc921c2b4fe647de62b81"
    }
  },
  {
    "ts": null,
    "headline": "Metsera Tumbles After Novo Pulls Out of Bidding War With Pfizer",
    "summary": "The shares slumped as much as 16% to $70.12 in US premarket trading.  The stock more than quadrupled from its January initial public offering through Friday’s close.  Novo, the maker of Wegovy and Ozempic, decided to drop out of the running for Metsera on Saturday after Pfizer matched its latest offer in a takeover battle that had caused concern the bidders might be overpaying for an unproven asset.",
    "url": "https://finnhub.io/api/news?id=9cfc87e1a60a6b440b98f541fcd1eb8368768c7472e1a524928cdf933752b164",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762775717,
      "headline": "Metsera Tumbles After Novo Pulls Out of Bidding War With Pfizer",
      "id": 137395049,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The shares slumped as much as 16% to $70.12 in US premarket trading.  The stock more than quadrupled from its January initial public offering through Friday’s close.  Novo, the maker of Wegovy and Ozempic, decided to drop out of the running for Metsera on Saturday after Pfizer matched its latest offer in a takeover battle that had caused concern the bidders might be overpaying for an unproven asset.",
      "url": "https://finnhub.io/api/news?id=9cfc87e1a60a6b440b98f541fcd1eb8368768c7472e1a524928cdf933752b164"
    }
  },
  {
    "ts": null,
    "headline": "Scholar Rock: De-Risked Biotech, Playing The Approval Catalyst (Buy Rating)",
    "summary": "Discover why Scholar Rock is a speculative biotech buy on Apitegromab phase 3 results.",
    "url": "https://finnhub.io/api/news?id=c1378b757cf707f48cecc23fe026e4a2fc5175b66ab6256d754796e783d9cc18",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762774091,
      "headline": "Scholar Rock: De-Risked Biotech, Playing The Approval Catalyst (Buy Rating)",
      "id": 137395771,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2223838895/image_2223838895.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Discover why Scholar Rock is a speculative biotech buy on Apitegromab phase 3 results.",
      "url": "https://finnhub.io/api/news?id=c1378b757cf707f48cecc23fe026e4a2fc5175b66ab6256d754796e783d9cc18"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Gets Metsera: Why The $20.65 CVR Is Highly Likely To Pay Out (In Part)",
    "summary": "Pfizer Inc. acquires Metsera, Inc., beating Novo Nordisk, for up to $86.25/share. Click for my analysis of the deal and what I see in store for PFE and MTSR stock.",
    "url": "https://finnhub.io/api/news?id=cf5998ed79d06be24d3bc5130230208e6e11e86c6a0530d9c04fde6ba532c62a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762774044,
      "headline": "Pfizer Gets Metsera: Why The $20.65 CVR Is Highly Likely To Pay Out (In Part)",
      "id": 137395772,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1292440985/image_1292440985.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer Inc. acquires Metsera, Inc., beating Novo Nordisk, for up to $86.25/share. Click for my analysis of the deal and what I see in store for PFE and MTSR stock.",
      "url": "https://finnhub.io/api/news?id=cf5998ed79d06be24d3bc5130230208e6e11e86c6a0530d9c04fde6ba532c62a"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer to Acquire Metsera Under Amended Deal; Novo Nordisk Says No Plan to Increase Offer for Metsera",
    "summary": "Metsera (MTSR) said late Friday it signed an amended merger agreement with Pfizer (PFE) under which",
    "url": "https://finnhub.io/api/news?id=4f9c2a4248381470527922488cac8b98672ff7c5e8740619d97f008257b85355",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762769143,
      "headline": "Pfizer to Acquire Metsera Under Amended Deal; Novo Nordisk Says No Plan to Increase Offer for Metsera",
      "id": 137395050,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Metsera (MTSR) said late Friday it signed an amended merger agreement with Pfizer (PFE) under which",
      "url": "https://finnhub.io/api/news?id=4f9c2a4248381470527922488cac8b98672ff7c5e8740619d97f008257b85355"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer CEO: Metsera deal gives us 'one of the most exciting, advanced portfolios' in obesity drugs",
    "summary": "Pfizer CEO Albert Bourla joins Squawk on the Street to discuss the company’s up to $10 billion acquisition of Metsera, the competitive landscape in obesity drugs, and Pfizer’s strategy for clinical development and manufacturing.",
    "url": "https://finnhub.io/api/news?id=314d2a10636205cc877da1c47efbae48479c2a8e4d7c0f5f90d27880e238f463",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762769131,
      "headline": "Pfizer CEO: Metsera deal gives us 'one of the most exciting, advanced portfolios' in obesity drugs",
      "id": 137396189,
      "image": "https://image.cnbcfm.com/api/v1/image/108223604-17627866371762786630-42491514766-1080pnbcnews.jpg?v=1762786636&w=1920&h=1080",
      "related": "PFE",
      "source": "CNBC",
      "summary": "Pfizer CEO Albert Bourla joins Squawk on the Street to discuss the company’s up to $10 billion acquisition of Metsera, the competitive landscape in obesity drugs, and Pfizer’s strategy for clinical development and manufacturing.",
      "url": "https://finnhub.io/api/news?id=314d2a10636205cc877da1c47efbae48479c2a8e4d7c0f5f90d27880e238f463"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Shares Rise After Withdrawal from Metsera Takeover Battle",
    "summary": "Shares climbed as much as 3.5% in early European trade after Pfizer agreed to buy Metsera in a deal that could be worth more than $10 billion following a heated takeover battle.",
    "url": "https://finnhub.io/api/news?id=67303b4d217126cdb4558ef90efd6643372860e362a5d7b232fd67c3f6487cea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762767480,
      "headline": "Novo Nordisk Shares Rise After Withdrawal from Metsera Takeover Battle",
      "id": 137395051,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Shares climbed as much as 3.5% in early European trade after Pfizer agreed to buy Metsera in a deal that could be worth more than $10 billion following a heated takeover battle.",
      "url": "https://finnhub.io/api/news?id=67303b4d217126cdb4558ef90efd6643372860e362a5d7b232fd67c3f6487cea"
    }
  },
  {
    "ts": null,
    "headline": "Norway wealth fund abstains from Novo board vote; Stock up on dropped Metsera bid",
    "summary": "Investing.com -- Norway’s sovereign wealth fund said on Monday it will abstain from voting on new board members, including the chair, at Novo Nordisk’s extraordinary shareholders’ meeting on November 14.",
    "url": "https://finnhub.io/api/news?id=763c0dcffb779b9d0b99bb3e21cf89104385cb7c5862549ebb605b3aa3816b08",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762766245,
      "headline": "Norway wealth fund abstains from Novo board vote; Stock up on dropped Metsera bid",
      "id": 137395052,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Investing.com -- Norway’s sovereign wealth fund said on Monday it will abstain from voting on new board members, including the chair, at Novo Nordisk’s extraordinary shareholders’ meeting on November 14.",
      "url": "https://finnhub.io/api/news?id=763c0dcffb779b9d0b99bb3e21cf89104385cb7c5862549ebb605b3aa3816b08"
    }
  },
  {
    "ts": null,
    "headline": "LONDON MARKET EARLY CALL: FTSE 100 seen up on hopes of US shutdown end",
    "summary": "LONDON MARKET EARLY CALL: FTSE 100 seen up on hopes of US shutdown end",
    "url": "https://finnhub.io/api/news?id=79599ae15565bdac463bee17a67ac1727f6f097d63110b4ac3332c897adb8c79",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762757581,
      "headline": "LONDON MARKET EARLY CALL: FTSE 100 seen up on hopes of US shutdown end",
      "id": 137393131,
      "image": "",
      "related": "PFE",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=79599ae15565bdac463bee17a67ac1727f6f097d63110b4ac3332c897adb8c79"
    }
  },
  {
    "ts": null,
    "headline": "Dividend Income: Lanny's September 2025 Summary",
    "summary": "In September, we (my wife and I) received a dividend income total of $5,342.09. wild! A $5,000 month.",
    "url": "https://finnhub.io/api/news?id=822959e58eef96b118511fd4f78c6a5204c1d3c198da63cfb46b3f16c9501828",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762752420,
      "headline": "Dividend Income: Lanny's September 2025 Summary",
      "id": 137393614,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2209914068/image_2209914068.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "In September, we (my wife and I) received a dividend income total of $5,342.09. wild! A $5,000 month.",
      "url": "https://finnhub.io/api/news?id=822959e58eef96b118511fd4f78c6a5204c1d3c198da63cfb46b3f16c9501828"
    }
  },
  {
    "ts": null,
    "headline": "Europe markets close higher as hopes of an end to U.S. government shutdown spill over",
    "summary": "European stocks rallied on Monday as a deal that could end the U.S. government shutdown appears to be getting closer.",
    "url": "https://finnhub.io/api/news?id=0292d45f2858fa4445f818916f9362ae3f460cb646dd35e471fcfaf919d57e47",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762738974,
      "headline": "Europe markets close higher as hopes of an end to U.S. government shutdown spill over ",
      "id": 137396190,
      "image": "https://image.cnbcfm.com/api/v1/image/107182861-1674559937813-gettyimages-1449558958-ln1_0819_andkvtyb.jpeg?v=1674569636&w=1920&h=1080",
      "related": "PFE",
      "source": "CNBC",
      "summary": "European stocks rallied on Monday as a deal that could end the U.S. government shutdown appears to be getting closer.",
      "url": "https://finnhub.io/api/news?id=0292d45f2858fa4445f818916f9362ae3f460cb646dd35e471fcfaf919d57e47"
    }
  }
]